Clinical Trial: Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo(R) in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07221734) titled 'Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo(R) in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma' on Oct. 06.

Brief Summary: This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo(R) in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Advanced (Unresectable or Metastatic) Melanoma

Intervention: DRUG: MB11 (Proposed Nivolum...